Mustang Bio, Inc. announced that its IL13Ra2-targeted CAR T-cell therapy, MB-101, received Orphan Drug Designation from the FDA for treating recurrent diffuse and anaplastic astrocytomas and ...
Adaptin Bio has obtained IND clearance from the FDA for APTN-101 in glioblastoma, enabling initiation of a first-in-human phase I trial in patients diagnosed with WHO grade IV malignant glioma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results